氟替卡松糠酸酯

Name	FLUTICASONE FUROATE
Synonyms	AvaMys Veramyst AllerMist Gw 685698x Unii-js86977wnv (6α,11β,16α,17α)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-Methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(FluoroMethyl) Ester Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-
CAS	397864-44-7
EINECS	222-789-2

Molecular Formula	C27H29F3O6S
Molar Mass	538.58
Density	1.39
Melting Point	250-252°C (dec.)
Boling Point	625.2±55.0 °C(Predicted)
Solubility	Chloroform (Slightly, Heated, Sonicated), Methanol (Slightly)
Appearance	Solid
Color	White to Off-White
pKa	12.52±0.70(Predicted)
Storage Condition	-20°C Freezer
In vitro study	Fluticasone furoate comes in a nasal spray, as an aqueous suspension of micronized fluticasone furoate for topical administration to the nasal mucosa by means of a metering, atomizing spray pump. Fluticasone furonate displays great potency in inhibiting tumor necrosis factor synthesis and action. Fluticasone furonate is also potent in preventing damage to cultured human lung epithelial cells by different stimulus.
In vivo study	Fluticasone furonate is 99.4% bound to plasma protein in vitro and other research indicated extensive first-pass metabolism of the absorbed drug. Protein binding is highly relevant because only the unbound free drug can exert an effect at the receptor site. Clearance of Fluticasone furonate is primarily by hydrolysis in the liver by the cytochrome P450 isozyme (CYP) 3A4 that converts the drug to the 17β-carboxylic acid metabolite (M10), which displays low glucocorticoid receptor agonist potency. Fluticasone furonate is excreted mainly in the feces, with only minor amounts in the urine.